Inhibrx Biosciences CEO Mark Lappe reports purchase of 10,040 shares for $848,976.8365
INBX•CEO and director Mark Lappe purchased 10,040 Inhibrx Biosciences common shares through two trusts for $848,976.8365, according to the article.
1. Share purchase
Mark Lappe purchased 10,040 common shares through two trusts at reported prices of $84.0707, $84.9992 and $85.76 per share. His indirect beneficial ownership totaled 970,453 common shares after the purchases.
